fda warning compounded semaglutide october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compound versions of GLP-1 drugs

For more information, read the Partial Plan Guide

Our new Drug Channels analysis examines: how widely these programs are embedded in plan design how often theyre actually applied who bears the consequences why policy responses have only gone so far Read the full update here: To view or add a comment, sign in The data is here

Whether you are questioning if Medicare, Medicaid, or private insurers like United Healthcare cover semaglutide, our care team provides clear, upfront answers

T., & Levine, N

We not only have a branded drug on the shortage list, but we also have a blockbuster branded drug on the shortage list that has life changing implications for millions of patients